SVCM
TBPH icon

Saturn V Capital Management’s Theravance Biopharma TBPH Stock Holding History

Saturn V Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-141,339
Closed -$1.33M – 19
2022
Q4 		$1.33M Buy
+141,339
New +$1.49M 1.11% 19

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Saturn V Capital Management's TBPH Position: Q1 2023 in Review

Saturn V Capital Management sold out of Theravance Biopharma (TBPH) in Q1 2023, closing a stake of 141,339 shares — an estimated $1.33M sold.

Saturn V Capital Management first reported a position in TBPH in Q4 2022 and held it in 1 quarter. The position peaked at $1.33M in Q4 2022. 113 funds tracked by Wall St. Rank hold TBPH as of Q1 2023.

  • Saturn V Capital Management reported no remaining Theravance Biopharma position as of Q1 2023 after selling out during the quarter.
  • Saturn V Capital Management sold 141,339 Theravance Biopharma shares in Q1 2023, an estimated $1.33M.
  • Saturn V Capital Management first reported a position in Theravance Biopharma in Q4 2022 and held it in 1 quarter.
  • Saturn V Capital Management's Theravance Biopharma position peaked at $1.33M in Q4 2022.
  • 113 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2023.

Based on Saturn V Capital Management's 13F filing for Q1 2023, filed 15 May 2023.